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The airways of people with cystic fibrosis (CF) are often chronically 
colonised with a diverse array of bacterial and fungal species. 
However, little is known about the relative partitioning of species 
between the planktonic and biofilm modes of growth in the airways. 
Existing in vivo and in vitro models of CF airway infection are ill-suited 
for the long-term recapitulation of mixed microbial communities. Here 
we describe a simple, in vitro continuous-flow model for the cultivation 
of polymicrobial biofilms and planktonic cultures on different 
substrata. Our data provide evidence for inter-species antagonism 
and synergism in biofilm ecology. We further show that the type of 
substratum on which the biofilms grow has a profound influence on 
their species composition. This happens without any major alteration 
in the composition of the surrounding steady-state planktonic 
community. Our experimentally-tractable model enables the 
systematic study of planktonic and biofilm communities under 
conditions that are nutritionally reminiscent of the CF airway 
microenvironment, something not possible using any existing in vivo 
models of CF airway infection.
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Research highlights
Scientific benefits
• Allows for direct comparison of biofilm and planktonic microbial lifestyles.
• Allows for longitudinal and real-time analysis of interspecies interactions among polymicrobial biofilms.
3Rs benefits
• Reduces the need for vertebrate infectionmodels when studyingmicrobe-microbe interactions in the context of
cystic fibrosis.
Practical benefits
• Inexpensive and simple to operate.
• Chemically defined culture conditions, allows for the reproducible study of subtle interspecies interactions.
• Experimentally tuneable, allows for different species combinations or disease states to be studied.
Current applications
• Studying changes in ecology of polymicrobial biofilm formation during co-culture on different solid substrata.
Potential applications
• Studying changes in gene expression and behaviour of polymicrobial biofilms comprising of different species
combinations.
• Studying response of polymicrobial biofilms and planktonic communities against treatment with antimicrobials
for the development and validation of polymicrobial biofilm dispersal/treatment regimens.
Introduction
Cystic fibrosis (CF) is a life-limiting genetic disorder estimated to affect 70,000 people worldwide (Cystic Fibrosis
Foundation). Although a systemic multi-organ disease, the most striking manifestation of CF is chronic obstruction of
the airways via an overproduction of viscous, nutrient-rich airway secretions. These secretions block the airways and
predispose people with CF to life-long microbial infection. These infections are frequently polymicrobial and comprise
both bacterial and fungal species (Ahmed et al., 2019; Boutin et al., 2015; Carmody et al., 2015; Hogan et al., 2016; Jorth
et al., 2019; Mahboubi et al., 2016; Rogers et al., 2010; Sibley and Surette, 2011; Zhao et al., 2012). CF airway infections
contribute towards a decline in pulmonary function and it is estimated that ~90% of persons with CF succumb to
respiratory failure as a direct result of microbial infection (Chmiel and Davis, 2003; Elborn, 2016; Lubamba et al., 2012;
Lyczak et al., 2002; Rajan and Saiman, 2002; Sibley et al., 2006).
Recent years have seen increasing recognition that inter-species interactions between the airway microbiota may play
a role in modulating the behaviour, virulence, and even the response to therapeutic intervention (Antonic et al., 2013;
Armbruster et al., 2016; Baldan et al., 2014; Barnabie and Whiteley, 2015; Beaume et al., 2015; Briaud et al., 2019;
Dalton et al., 2011; Diggle et al., 2007; Elias andBanin, 2012; Hotterbeekx et al., 2017; Hibbing et al., 2010; Korgaonkar
et al., 2013; Mastropaolo et al., 2005; O'Brien and Fothergill, 2017; Peters et al., 2012; Weimer et al., 2010). Moreover,
co-culturing bacterial species in vitro and in vivo has been shown to lead to significant alterations in the expression of core
essential genes (Ibberson et al., 2017; Ibberson and Whiteley, 2020). One particularly important unaddressed question
relates to the impact of co-habiting species on the biology of Pseudomonas aeruginosa (PA). PA is a common inhabitant
of the CF airways, and a model organism for the study of biofilms. However, the paucity of experimentally tractable
in vivo or in vitromodels of CF infection has severely hampered the in-depth and longitudinal study of such polymicrobial
communities (O'Brien and Welch, 2019b).
It has been estimated that at least 60% of bacterial infections in the western world involve the formation of biofilms (Fux
et al., 2005) and CF is no exception. One crucial feature of microbial biofilms is their increased ability to bypass effective
immune clearance and resist antimicrobial action. Indeed, some bacterial biofilms are up to 1000  more resistant to
antimicrobial intervention comparedwith their planktonic cell counterparts (Parsek, 2003). The formation of biofilm-like
aggregates in the CF airways is often cited as a reason why therapeutic strategies aimed at eradicating keystone CF
pathogens such as PA fail (Bjarnsholt et al., 2009; Döring et al., 2011; Elias and Banin, 2012; Folkesson et al., 2012;
Leekha et al., 2011; Lopes et al., 2012; Lopes et al., 2014; Mowat et al., 2011). However, our understanding of how
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inter-species interactions alter biofilm physiology remains limited. This is important because agonistic and antagonistic
interactions between species almost certainly confer a significant selection pressure, thereby driving adaptive divergence
inmembers of the polymicrobial community (Markussen et al., 2014; Schick andKassen, 2018;Winstanley et al., 2016).
There are three key vertebrate models of CF available to researchers: the CF mouse, the CF ferret and the CF pig
(reviewed recently by O'Brien and Welch, 2019b). Although the porcine airways share a remarkable degree of genetic
and structural homology with human airways (Judge et al., 2014; Rogers et al., 2008), the cost and technical/ethical
complexity of using porcine models ensures they are rarely used in research. CF ferrets are also rarely used, since they
develop severe airway infections soon after birth and subsequently succumb to respiratory failure (Hoffman and Hajjar,
2018; Sun et al., 2010), although this situation may change as in utero administration of cystic fibrosis transmembrane
conductance regulator (CFTR)modulators can rescue this severe phenotype (Sun et al., 2019). By contrast, the CFmouse
is widely used, with >14 different distinct models available (Guilbault et al., 2007). However, and despite the widespread
availability of these murine CF models, their usefulness for studying chronic airway infection is limited. CF mice do not
develop spontaneous airway infections (Bayes et al., 2016; Cash et al., 1979; vanHeeckeren et al., 2006), and artificially-
induced infections of the airways are rapidly cleared if the inoculated microbial species are not immobilised using agar/
agarose/alginate beads (Chattoraj et al., 2010; Hoffmann et al., 2005; Moser et al., 2009; Munder et al., 2011). As with
CF ferrets, this prevents the long-term study of polymicrobial communities and interspecies interactions.
Due to inherent limitations in the way in which the data is reported, the exact number of animals used for research
into CF airway infections is difficult to ascertain. Yet a systematic review of the literature up to 2015 has found 12,304
publications discussing the use of CF animal models. Of those that are primary research articles (799 publications),
636 report the use of CF mice, rats, pigs, ferrets or zebrafish (with the remaining publications not reporting the use of
any genetic CF models) (Leenaars et al., 2020). Given that this literature review only accounts for publications up to
2015, and given the recent surge of interest into understanding the polymicrobial communities associated with CF
airway infections, the number of CF animals used in research will have certainly increased over the last six years. Despite
the importance of biofilms in CF pathology, and their well-known link with increased patient mortality rates, there is
currently no suitable in vivomodel for the study of polymicrobial biofilm communities in the context of CF. Furthermore,
none of the aforementioned 636 studies report the use of CF models to study polymicrobial biofilm communities.
Practical limitations when sampling the airway microbiota in infected animal models mean that the animals must be
sacrificed and their lungs excised before histopathological examination. Not only are there significant ethical implica-
tions associated with these approaches, but the longitudinal/long-term study of microbial populations becomes imprac-
tical. More recently, ex vivo models of CF have redressed some of these issues, enabling the study of microbial biofilm
lifestyles reminiscent of those observed in situ (Harrington et al., 2020; Sweeney et al., 2021). However, owing to the
intense competition observed among microbial species, existing ex vivomodels do not yet permit the study of more than
one microbial species at a time. This is a significant experimental limitation when studying long-term polymicrobial
infection scenarios such as CF. Hence, the in vitromodel we describe here provides a novel tool for the study of mixed-
species biofilms that is not currently possible using existing in vivo CF models.
The primary limitations of in vitro infection models, compared with in vivomodels, is a lack of host cells and a functional
immune system (which may contribute towards clearing microbial infections in situ). However, it should be noted that
impaired immune clearance of microbes in an inherent feature of CF, which somewhat mitigates the lack of a functional
immune system in in vitro models (Cohen and Prince, 2012; Bonfield and Chmiel, 2017). Although in vitro models do
not capture all aspects of human disease pathophysiology, they do provide an ideal tool for studying interspecies
interactions between microbes (O'Brien and Welch, 2019b). Emerging evidence suggests that chemical, not spatiotem-
poral, factors have the greatest impact on driving changes in microbial lifestyles (Lopes et al., 2017; Quinn et al., 2015).
Hence, the defined and experimentally-perturbable nature of in vitro models are an attractive option for studying
microbial behaviour in a reductive manner. Furthermore, the development of artificial sputum medium (ASM), closely
mimicking the nutritional composition of CF airway secretions, provides an unparalleled opportunity for the study of
polymicrobial populations under conditions that chemically recapitulate the CF microenvironment (Haley et al., 2012;
Sousa et al., 2018; Sriramulu et al., 2005; Turner et al., 2015; Frapwell et al., 2018). However, simplymixing CF airway-
associated species together in ASM and hoping for the best is not a recipe for success. This is because the co-cultures
display compositional instability, and the initially diverse community rapidly become dominated by just one or a few
species. To remedy this, we developed an in vitro model of CF (O'Brien and Welch, 2019a). Importantly, our model
permits planktonic microbial communities of three distinctly different species associated with CF airway infections
(PA, Staphylococcus aureus (SA) and Candida albicans (CA)) to be maintained, indefinitely, as a stable steady-state
community. In this report we build upon our existing model and describe a simple, yet versatile, method of culturing
polymicrobial biofilms on different solid substrata.
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The model described in this work permits the simultaneous cultivation of steady-state planktonic and biofilm commu-
nities, allowing for direct comparisons to be made between these two modes of microbial growth. In principle, any
combination of microbial species associated with CF airway infections could be cultured using the setup. As such, not
only does our system reduce the need for in vivo CF infection models for studying microbe-microbe interactions; it
enables the real-time, longitudinal study of polymicrobial communities in an experimentally reproducible, controlled
setup. It has not escaped our notice that this model system is also well-suited for the road-testing of interventions aimed at
preventing the formation of biofilms in chronic CF airway infections.
Methods
Methods for the model development
Microbial strains
All microbial strains used in this work are shown in Table 1. Strains were routinely cultured in lysogeny broth (LB)
(Formedium) on a 40 cm diameter rotating drum with mild aeration (0.5 rotations per second) at 37°C overnight.
Continuous-flow culture vessel and biofilm container
Artificial sputum medium (ASM) was used as the main growth medium for all experiments and was prepared as
previously described (O'Brien and Welch, 2019a). The continuous-flow culture system has also been previously
described (O'Brien and Welch, 2019a). Both are described in more detail in the protocol below. Briefly, the culture
vessel consists of a 100 mL Duran flask, fitted with an assembled 4-port HPLC GL80 screw cap (Duran). A 24-channel
IPC ISM934C standard-speed digital peristaltic pump (Ismatec) was used to deliver sterile ASM from amedia reservoir at
a defined flowrate (Q) through 1.5 mm bore sterilin silicon tubing (Fisher Scientific) to the culture vessel. A different
channel of the same pump was used to remove waste culture into a discard jar at the same flowrate (Figure 1). Biofilms
Figure 1. Schematic diagram of the continuous-flow culture vessel containing biofilm container. The main
culture vessel (centre) is a 100mL Duran bottle fitted with a 4-port HPLC GL80 screwcap lid, containing four sealable
inlet/outlet ports from which the biofilm container is suspended. A multichannel peristaltic pump delivers fresh
media (ASM) into the culture vessel from a reservoir (left), and also removes waste culture into a discard jar (right) at
the same rate of flow (Q). Arrows show the direction of media flow. The culture vessel and media reservoirs are
incubated at 37°C and the contents are kept homogenous through gentle stirring (100 rpm). The value ofQ depends
on the microbial species being cultured within the vessel.
Table 1. Microbial strains used in this study.
Strain Description Reference
PAO1 Pseudomonas aeruginosa, spontaneous chloramphenicol-resistant





Staphylococcus aureus Rosenbach (ATCC®25923D-5™), methicillin sensitive
clinical isolate. Laboratory reference strain lacking recombinases andmecA
(isolated Seattle, 1945)
(Treangen et al., 2014)
SC5314 Candida albicans, clinical isolate commonly used as a wild-type laboratory
reference strain (isolated New York, 1980’s)
(Gillum et al., 1984)
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were allowed to develop in the continuous-flow culture vessel on two types of solid substratum; agar chunks and
ex vivo porcine lung tissue (EVPL) sections, which have been previously reported to closely mimic the airway surface
environment (Harrison et al., 2014; Harrison and Diggle, 2016; Sweeney et al., 2021; Harrington et al., 2020). These
substrata were suspended in bespoke cylindrical biofilm containers (25 mm diameter 35 mm length) constructed from
stainless steel wire gauze (Fisher Scientific) (Figure 2A,B). Containers were then suspended in the culture vessel hanging
from a piece of silicon tubing threaded through two of the unused HPLC ports (Figure 2C). The entire culture systemwas
maintained at 37°C and the liquid contents of the vessel were kept homogenous by stirring (100 rpm) using a round
magnetic stir bar (length 20 mm, diameter 8 mm).
Preparation of biofilm substratum
Agar plates (2.5%w/v agar inmilliQwater) were poured to a depth of 5mm.Using a sterile number 21 scalpel and a set of
sterile 12.7 cm curved forceps, cubes of approximately 5 mm x 5 mm were cut from the plate and transferred into the
sterile biofilm container. Biofilmwork usingEVPL sectionswas performed in collaborationwithDr FreyaHarrison at the
Figure 2. Container for culturing biofilms under continuous-flow conditions. The biofilm container constructed
from stainless steel gauze for this study. Biofilm containers consisted of a cylinder, 35 mm in length and 25 mm
in diameter (Ø), connected to two stainless steel arms (45 mm in length), which suspend the container from the
HPLC screw-port lid. (A) Side view of the container with dimensions. (B) Bottom view of the container. Single strands
of stainless-steel wire were threaded across the bottom of the container to form a mesh and prevent the biofilm
substratum from falling through. A small gap (~3mmØ) was also included for theoutlet tube to be threaded through
to allow the removal of culturemedia during incubation. (C) View of the 4-port HPLC screw cap lid. The left port is the
media inlet, the right port is themedia outlet and the two remaining ports are threadedwith a single piece of rubber
tubing (1.5mmbore) to hold the arms of themesh container. (D) The biofilm container in situ in the assembled setup.
Note that the container is completely submerged in the growthmedium but is separated from themagnetic stir bar
to prevent interference with the continual stirring of the culture vessel.
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University of Warwick, using previously described methods (Harrison and Diggle, 2016). Briefly, fresh pig lungs were
collected from the butcher (John Taylor, Earlsdon, UK) and processed within the hour. To remove surface contaminants,
a 25 cm palette knife was heated until red-hot using a Bunsen burner and briefly tapped (< 1 s) on the area to be dissected.
Working with aseptic technique, a sterile razor blade was used to excise the bronchiole and remove all alveolar tissue; a
cleaned bronchiole can be seen in Figure 3. Bronchioles were washed in Dulbecco's Modified Eagle Medium (DMEM)/
Roswell Park Memorial Institute 1640Medium (RPMI) solution (50:50 ratio, 40 mL) and cut into 5 mmwide strips with
sterile dissection scissors. The strips were washed in DMEM/RPMI and cut into 5 mm 5 mm squares. EVPL sections
werewashed again inDMEM/RPMI, then transferred to a petri dish containing 40mLASMand irradiated inUV lightbox
for 5 min before being aseptically transferred to the biofilm container [Full dissection methods for the production of
EVPL tissue sections are also demonstrated in an open access video protocol (Harrington et al., 2021)].
Culture vessel inoculation and incubation
Overnight cultures of the microbial strains (grown in LB as described above) were washed three times in phosphate-
buffered saline (PBS) prior to inoculating the culture vessel. Pre-warmed ASM (37°C, 100 mL) was added to the culture
vessel and inoculated with the required combination of microbial species. The optical density (at 600 nm; OD600 nm) of
the washed microbial cultures was then measured using a spectrophotometer (Eppendorf BioSpectrometer kinetic)
and each species was introduced into the culture vessel to achieve a starting OD600 nm of 0.05. The culture vessel was
then incubated for three hours with stirring prior to starting the flow of medium (Q = 145 μL min1).
Sample collection
For characterisation of biofilm populations, pieces of substratum were aseptically removed at the indicated times
and transferred to 500 μL PBS in 24-well microtiter plates. Loosely attached planktonic cells were removed from the
substratum by briefly swirling the plates. The substratum was then transferred to a second well in the same plate and
washed oncemore. Finally, after a third wash, the samples were transferred into 2mL bead beating tubes containing 1mL
PBS and eighteen metal beads (2.38 mm diameter, Qiagen). The tubes were them agitated in a FastPrep-24 5G benchtop
homogeniser (MP Biomedicals) for 40 s at 4 m s1 to liberate the cells. CFU mL1 counts were performed as described
below. Three separate substratum pieces were sampled at each time point (yielding three biological replicates per
timepoint, per independent biological experiment). Samples of the planktonic culture (1 mL) were removed directly from
the culture vessel using a sterile serological pipette. Independent biological experiments were then performed over
separate independent weeks using fresh microbial cultures and pieces of biofilm substratum without any deviation from
the methods detailed in this article.
CFU mL1 enumeration
Colony forming units (CFU) were determined using the single plate-serial dilution spotting method, as described
previously (Thomas et al., 2015). Briefly, 10-fold serial dilutions of the microbial cultures were made in sterile PBS
and 20 μL of each dilution was spotted (approximately 2 μL per drop) onto the appropriate selective agar. Three types of
Figure 3. Ex vivo porcine bronchiole. A single bronchiole excised from porcine lung tissue after cleaning and a
single wash in DMEM/RPMI solution. All alveolar and vascular tissue was removed using a razor blade and dis-
section scissors. After cleaning, bronchiole tissue was cut into 5 mm 5 mm squares for use as solid substratum to
promote biofilm growth.
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selective agar were used to enumerate microbial cell counts of the different species present in a single sample: PA was
isolated usingPseudomonas isolation agar (PIA, Oxoid), SAwas isolated usingmannitol salt agar (MSA,Oxoid) and CA
was isolated onto BiGGY agar (Oxoid). When enumerating cell counts from the polymicrobial cultures, the agar plates
used to isolate PA and SA were further supplemented with 5 μg mL1 itraconazole to inhibit the growth of CA. The
different selectivemedia only permit the growth of a singlemicrobial species of interest and inhibit the growth of the other
species present. This enables CFU mL1 counts for each species in the polymicrobial culture to be determined with
confidence [note that when studying other co-cultures containing other combinations ofmicrobial species, different types
of selective media may be required for the selective enumeration of other species]. All plates were incubated at 37°C.
PIA andMSA plates were incubated overnight (16 h) and BiGGY agar plates were incubated for 24 h. Three independent
samples of biofilm substratum from the same culture vessel were removed per timepoint (corresponding to three
biological replicates). For each biological replicate, three independent serial dilutions were made and plated out for
CFU enumeration (constituting three technical replicates per each piece of substratum sampled), non-blinded CFUmL1
counts were then recorded as the average of the technical replicates. Two independent samples of culture supernatant
were removed from each culture vessel per timepoint (corresponding to two technical replicates) to enumerate planktonic
CFU mL1 counts of each species.
We tested whether there was any significant difference in cell counts determined on non-selective vs selective agar, and
there was not (Figure 4 and underlying data (O'Brien et al., 2021)). To test this, we performed serial dilutions of overnight
microbial cultures (routinely grown in LB as described above) and plated the same dilution series onto LB-agar (non-
selective) and the appropriate selective agar for the cultured species [see notes above]. Plates were then incubated in the
same static incubator at 37°C. Plates containing PA or SA incubated for 16 h and plates containing CA incubated for 24 h
(as described above). Two independent serial dilutions of the same overnight culture were prepared and plated in parallel
from the same overnight culture (constituting two technical replicates) and three independent biological replicates for each
microbial species were performed across separate days using fresh microbial cultures and freshly prepared agar plates.
Statistical analysis
All biofilm data are represented as the mean  standard deviation (SD) of three separate biological replicates (collected
simultaneously from the same culture vessel at each point of sampling) per timepoint across three independent biological
experiments (conducted across different weeks) that were performed using fresh: ASM, microbial cultures and pieces of
biofilm substrata [note that experiments using agar chunks or EVPL sections were performed independently of one
another]. All planktonic data are represented as the mean standard deviation (SD) of two technical replicates (collected
simultaneously from the same culture vessel) per timepoint across three independent biological experiments. Planktonic
and biofilm CFU mL1 counts were performed in parallel from the same culture vessel. All statistical analysis was
performed using GraphPad Prism version 8.2.0, with P < 0.05 being considered statistically significant [statistical
analysis can also be performed using R/Python packages stats/SciPy, respectively]. Paired group two-tailed t-tests were
used to analyse: changes in CFUmL1 counts of the different species present in single- or mixed-species biofilm samples
collected at T = 24 h or 96 h; differences in CFU mL1 counts of the microbial species present on either agar chunks
or EVPL sections; and for comparisons of cell viability on selective and non-selective media. Changes in planktonic
Figure 4. Comparison of cell titres on selective and non-selective agar. The figure shows the viable cell counts
(expressed as CFU mL1) of overnight single-species cultures of P. aeruginosa PAO1 (PA), S. aureus 25923 (SA) and
C. albicans SC5314 (CA) plated on non-selective agar media (black bars) and selective agar media (grey bars). Data
represent themean standard deviation from two technical replicates collected from three independent biological
experiments. P > 0.05 is considered as not significantly different (ns).
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CFUmL1 counts across the timepoints for each experiment were analysed using one-way repeated measures ANOVA.
Differences in planktonic CFU mL1 counts in cultures containing the different biofilm substrata across the timepoints
for each experiment were analysed using two-way repeated measures ANOVA.
Protocol for the use of this model
Here we describe step-by-step the procedure used to prepare ASM and to set up/inoculate the continuous-flow culture
vessel for the study of polymicrobial biofilm and planktonic communities. Reagents and equipment used in this study are
listed in Table 2 and Table 3, respectively.
1. Step 1 Assembly of the biofilm containers. This can be done any time prior to making ASM. A wire “bucket”
was crafted by hand from stainless steel wire gauze (Fischer Scientific). Figure 2 shows an image of a
completed container and dimensions.Wire cutters are used to trim amesh of stainless-steel gauze to a rectangle
approximately 150 mm x 40 mm. The gauze was then carefully rolled into a cylinder with an approximate
diameter of 25 mm. The protruding cut ends of the wire mesh on the side of the cylinder were threaded through
the adjacent mesh to secure the side of the cylinder in place. The height of the bucket was then adjusted to
35 mm via trimming with the wire cutters. Spare lengths of wire thread were then woven across the base of
the container to generate a bucket-like structure (Figure 2B). Note that we ensured that there was a hole in the
bottom of the bucket large enough to fit the out-flow tubing (~ 3mm diameter) (Step 6). To keep the stainless-
steel container from interfering with the magnetic stirrer, and to allow easy removal of substratum material
during cultivation, we suspended the bucket via two wire “arms” from a loop of silicone tubing threaded
through two unused ports of the HPLC screw cap lid (Figure 2C). The wire arms were made by entwining three
strands of stainless-steel wire and threading these through the mesh at the top of the bucket. The protruding
portion of the arms were bent to allow the bucket assembly to be draped over the silicone tubing support loop
and trimmed in length to 45 mm. The correct length of these container arms is important to ensure that the
bucket is completely submerged in the culture medium throughout incubation (Figure 2D).
2. Step 2 Preparation of ASM (day 1). Add 5 g of Type II mucin from porcine stomach to 250 mL phosphate
buffered saline (pH 7.4) and leave to dissolve overnight with stirring (~400 rpm) at 4°C. On the same day, add
4 g of deoxyribonucleic acid from salmon sperm to 250 mL autoclaved milliQ water and leave to dissolve
overnight in a shakingwater bath (200 rpm, 30°C).While themucin/DNA is dissolving, prepare the amino acid
and salt/buffer stock solutions (50 mL of each) according to Table 4. Most amino acid stock solutions can be
kept for one month in the dark at 4°C. However, stock solutions of tyrosine, threonine, cysteine, phenylalanine
and histidine must be made freshly for each batch of ASM.
3. Step 3 Preparation of ASM (day 2). Add ammonium chloride (0.124 g), potassium chloride (1.116 g), sodium
chloride (3.032 g) and 3-(N-morpholino) propanesulfonic acid (MOPS, 2.092 g) to a 1 L beaker and dissolve in
250 mLmilliQ water with gentle stirring (50 rpm). Then add the remaining salts and amino acids from the pre-
made stock solutions as shown in Table 4. Next, combine the dissolved DNA and mucin solutions and add to
the beaker with gentle mixing (50 rpm) for 5 min, or until the solution is homogenous. Adjust to pH 6.8 with
0.1M acetic acid or 0.1Mpotassium hydroxide. Following this, prepare the remainingmedia solutions and add
them to the beaker according to Table 5 alongside 5mL egg yolk emulsion. Once fully homogenous, adjust the
total volume to 1 LwithmilliQwater. TheASM is then filter sterilised using a 1 L disposable Stericup filter unit
(0.22 μMpore size) attached to a large diaphragmvacuumpump.Note that the filtering process is slow andmay
take 2–3 days to complete. Half-way through filtering we recommend carefully decanting (into a clean beaker)
the unfiltered ASM from the Stericup unit and rinsing the top of the filter membrane with several mL of sterile
PBS (that is then discarded) and then continuing with the filtration to speed up this process.
4. Step 4Assembly of continuous-flow culture vessel (day 3). While the ASM is being filter-sterilised, assemble
the continuous-flow culture vessel as outlined belowwith inclusion of the biofilm bucket constructed in Step 1.
The continuous-flow culture vessel consists of a 100 mL Duran flask fitted with an assembled GL-80 4-port
HPLC screw cap (Duran). Two lengths of 1.5 mm bore sterlin silicone tubing (Fisher Scientific) were fed into
two of the HPLC ports to act as an inlet/outlet (respectively) for the medium. To prevent contamination of the
media reservoir withmotile bacteria, ensure that only the outlet tube is in contact with the culturemediumwhen
the vessel is filled with ASM. A short piece of silicone tubing was threaded through the two-remaining unused
HPLC ports (diagonal from one another) and secured tightly before sealing any gaps around the HPLC ports
with parafilm. The biofilm bucket (assembled in Step 1) was hooked onto the suspended tubing and, using
forceps, the outlet tube was gently pulled through themeshed hole in the base of the bucket (see step 1). A clean
magnetic stir bar was placed in the culture vessel and the fully-assembled lid was fitted. Finally, the inlet tubing
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Table 2. Reagents used in this study.
Reagent Supplier [Catalogue Number]
Mucin from porcine stomach (Type II) Merck [M2378]
Deoxyribonucleic acid from salmon sperm Merck [31149]
Phosphate buffered saline Oxoid [BR0014G]
L-serine Merck [S4500]








L-ornithine hydrochloride Merck [W419001]
L-lysine hydrochloride Merck [W384712]
L-arginine monohydrochloride Merck [A5131]
L-tryptophan Merck [T0254]
L-asparagine monohydrate Merck [A8381]
L-tyrosine Merck [T3754]
L-threonine Merck [T8625]
L-cystine dihydrochloride Merck [C6727]
L-phenylalanine Merck [P2126]
L-histidine monohydrochloride monohydrate Merck [H8125]
Sodium phosphate monobasic anhydrous Fisher Scientific [7558-80-7]
Sodium phosphate dibasic anhydrous Fisher Scientific [7558-79-4]
Potassium nitrate Fisher Scientific [7757-79-1]
Potassium sulfate Fisher Scientific [7778-80-5]
Ammonium chloride Merck [12125-02-9]
Sodium chloride Fisher Scientific [7647-14-5]
Potassium chloride Fisher Scientific [7447-40-7]
MOPS [3-(N-morpholino)-propanesulfonic acid] Melford [1132-61-2]
D-(+)-glucose (dextrose) Merck [G7021]
L-(+)-lactic acid Merck [L1750]
Calcium chloride dihydrate Merck [10035-04-8]
Magnesium chloride hexahydrate Merck [7791-18-6]
Iron (II) sulfate heptahydrate Merck [7782-63-0]
N-acetyl-D-glucosamine Merck [A8625]
Egg yolk emulsion Millipore [17148]
Pseudomonas isolation agar Oxoid [CM0559]
Mannitol salt agar Oxoid [CM0085]
BiGGY-agar Oxoid [CM0589]
Agar Formedium [009002-18-0]
Lysogeny broth Formedium [LBX0102]
Dulbecco's Modified Eagle Medium Merck [D5030]
Roswell Park Memorial Institute 1640 Medium Merck [R8758]
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was wrapped in aluminium foil and the entire assembly was autoclaved. The setup was allowed to completely
dry overnight (in a drying cabinet) before use.
5. Step 5 Preparation of biofilm substratum (day 3). (i) Using agar chunks as a solid substratum for biofilm
formation, prepare the substratum by suspending 2.5 g of agar in 100 mL milliQ water. Autoclave. Once
cooled, but still warm (~65°C), pour the agar to a depth of 5 mm in a sterile 90mm petri dish. Once set, the agar
plates can be wrapped in parafilm and kept at 4°C until the day of use. (ii) Ex vivo porcine lung (EVPL) tissue
sections can also be used as an alternative substratum for biofilm formation. Please refer to Step 7 (day 4) for the
protocol detailing the inclusion of EVPL tissue sections in the model.
6. Step 6 Preparation of overnight microbial cultures (day 3). Place a nichrome 5 μL microbial inoculation loop
into the blue flame of a Bunsen burner for 5 s. Allow the loop to cool then pick a single microbial colony from
an agar plate and use to inoculate 10mL of LB in a sterile 30mL universal tube. Repeat for all microbial strains
to be inoculated into the culture vessel, then place the tubes on a rotating drum (200 rpm) and incubate at 37°C
overnight.
7. Step 7Preparation of EVPLbiofilm substratum (day 4). This workwas conducted in collaborationwithDr Freya
Harrison at the University of Warwick following their previously published protocol for the preparation of
EVPL sections (Harrison et al., 2014) Prior to culture vessel assembly and inoculation (see steps 8-9 below),
fresh pig lungs were collected from the butchers and processed within the hour. To remove surface contam-
inants, a 25 cm palette knife was heated using a Bunsen burner and briefly tapped (< 1 s) on the area to be
dissected. A sterile razor blade was used to excise the bronchiole and remove all alveolar tissue. Bronchioles
were then washed in DMEM/RPMI solution (40 mL, 50:50 ratio) and cut into 5 mm wide strips with sterile
dissection scissors. The stripswerewashed inDMEM/RPMI and cut into 5mm 5mmsquares. EVPL sections
Table 3. Equipment used in this study.
Equipment Supplier [Catalogue Number]
100 mL Duran Flask Merck [Z232076]
4-port HPLC GL80 Screw Cap Fisher Scientific [10583913]
24-channel IPC ISM934C Standard-speed Digital Peristaltic Pump Cole-Parmer [WZ-78001-42]
1.5 mm Bore Sterilin Silicon Tubing ThermoFisher [TSR0150150P]
Stainless Steel Wire Gauze Fisher Scientific [12958950]
Velp 6-position Multiposition Digital Stirrer Cole-Parmer [F203A0179]
Round White PTFE Magnetic Stir Bar, Length 20 mm x Diameter 8 mm Merck [HS120548]
Swann-Morton Number 21 Carbon Steel Scalpel Blade Fisher Scientific [11778363]
Epredia Shandon 12.7 cm Cartilage Fine Point Curved Thumb Forceps Fisher Scientific [15307805]
Epredia Shandon 16.5 cm Straight Dissecting Scissors (Sharp Ended) Fisher Scientific [15202290]
25 cm Eisco Palette Knife Spatula Fisher Scientific [S80827]
Azpack Carbon Steel Razor Blades Fisher Scientific [11904325]
Microspec 5 μL Nichrome Microbial inoculation Loop Fisher Scientific [15712175]
30 mL Polystyrene Universal Tube (Sterile) Starlab [E1412-3011]
Eppendorf BioSpectrometer Kinetic Eppendorf [6136000819]
2.38 mm Diameter Metal Beads Qiagen [13118-400]
2 mL PowerBead Beating Tubes Qiagen [13116-50]
FastPrep-24 5G benchtop homogeniser MP Biomedicals [116005500]
Stericup Quick Release-GP Sterile Vacuum Filtration System Merck [S2GPU10RE]
Nunc Cell-Culture Treated 24-well Plate ThermoFisher [142475]
Sterile 90 mm  15 mm Petri Dishes Merk [Z717223]
Bemis Parafilm M Laboratory Wrapping Fisher Scientific [HS234526B]
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L-serine 0.525 50 0.1 14.46 1.446 -
L-glutamic acid hydrochloride 0.918 50 0.1 15.492 1.549 -
L-proline 0.576 50 0.1 16.612 1.661 -
L-glycine 0.375 50 0.1 12.032 1.203 -
L-alanine 0.445 50 0.1 17.8 1.78 -
L-valine 0.586 50 0.1 11.172 1.117 -
L-methionine 0.746 50 0.1 6.332 0.633 -
L-isoleucine 0.656 50 0.1 11.212 1.121 -
L-leucine 0.656 50 0.1 16.092 1.609 -
L-ornithine hydrochloride 0.843 50 0.1 6.76 0.676 -
L-lysine hydrochloride 0.913 50 0.1 21.28 2.128 -
L-arginine
monohydrochloride
1.054 50 0.1 3.06 0.306 -
L-tryptophan 1.021 50 0.1 0.132 0.013 Prep in
0.2 M NaOH
L-asparagine monohydrate 0.666 50 0.1 8.272 0.827 Prep in
0.5 M NaOH
L-tyrosine 0.906 50 0.1 8.02 0.802 Prep in
1.0 M NaOH
Make fresh
L-threonine 0.596 50 0.1 10.72 1.072 Make fresh
L-cystine dihydrochloride 0.788 50 0.1 1.6 0.16 Make fresh




1.048 50 0.1 5.192 0.519 Make fresh
Sodiumphosphatemonobasic
anhydrous
1.380 50 0.2 8.125 1.3 -
Sodium phosphate dibasic
anhydrous
1.420 50 0.2 6.252 1.25 -
Potassium nitrate 5.056 50 1 0.348 0.348 -
Potassium sulfate 2.178 50 0.25 1.084 0.271 -

















D-(+)-glucose (dextrose) 4.504 25 1 1.2 3 -




3.67535 25 1 1.754 1.754 -
Magnesium chloride
hexahydrate
5.08275 25 1 0.606 0.606 -
Iron (II) sulfate
heptahydrate
0.05 50 0.0036 1 0.0036 Make fresh
N-acetyl-D-glucosamine 1.383 25 0.25 1.2 0.3 -
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were washed again in DMEM/RPMI, then transferred to a petri dish containing 40 mL ASM and irradiated in
UV lightbox for 5 min before being aseptically transferred to the biofilm container (as in Step 8).
8. Step 8 Assembly of the culture vessel (day 4). Working in a microbiological safety cabinet, cut the agar into
5 mm 5mm cubes using sterile (autoclaved) scalpel/forceps and aseptically transfer these into the wire mesh
container so that they sit loose (not stacked) at the bottom of the bucket. The number of substratum pieces used
for an experiment may differ, depending on the type of experiment, length of incubation and number of
time points to be sampled. In the current work, we simply report the microbial composition of polymicrobial
biofilms at two time points (T = 24 h and 96 h). Hence, only six pieces of substratum were incubated in the
culture vessel (three for each time point). However, we note that each biofilm container can easily hold 30+
pieces of substratum. Next, aseptically transfer 100 mL of fresh ASM to the culture vessel and secure the lid,
ensuring that the biofilm container does not interfere with the magnetic stir bar and is fully submerged in the
ASM. The inlet tubing was carefully unwrapped from the foil and placed into the remaining ASM (forming the
media reservoir) with the top sealed well with sterile parafilm to prevent contamination. Finally, place the end
of the outlet tubing into a discard jar and connect the inlet/outlet tubing to a peristaltic pump. Figure 1 shows a
schematic diagram of the assembled continuous-flow culture vessel. The entire system can then be primedwith
media. The setup was pre-warmed at 37°C prior to microbial inoculation.
9. Step 9 Culture vessel inoculation and incubation (day 4). In this report we describe the formation of
polymicrobial biofilms of Pseudomonas aeruginosa (PA), Staphylococcus aureus (SA) andCandida albicans
(CA), although in principle, any combination of microbial species could be used for co-culture. Overnight
cultures (prepared on day 3) of each species were washed three times in sterile PBS prior to inoculation. Once
washed, the optical density (OD600) of the cultures was measured and each species was introduced into the
culture vessel to achieve a starting OD600 of 0.05. The culture vessel was incubated at 37°C, with 100 rpm
stirring using a round PTFEmagnetic stir bar (8 mm diameter 20mm length), for three hours prior to starting
the flow of medium. For the current study, a continuous flow rate of 145 μL min1 was applied for the
remaining period of incubation (96 h). From our previous study (O'Brien and Welch, 2019a), we note that the
flow rate may need to be experimentally optimised if the goal is to maintain steady-state cultures of other
species or strains.
10. Step 10 Sample removal and viable cell counts (Day 4–9). At the desired time point(s) (in this study, T = 24 h
and 96 h for the biofilms and T = 24, 48, 72 and 96 h for the planktonic samples) remove 1 mL aliquots of the
liquid culture using a sterile serological pipette, or pieces of the biofilm substratum from the biofilm bucket, as
necessary. For enumeration of colony forming units (CFU mL1) from the biofilm samples, remove pieces
of solid substratum using sterile forceps, taking care to flame and cool the forceps between the collection of
individual samples. Pieces of the substratum were aseptically transferred to 500 μL sterile PBS in a 24-well
plate. To remove any loosely attached planktonic cells, gently swirl the plates for approximately 5 s then
transfer the substratum to another 500 μL of fresh PBS. Repeat the process two more times. A washed piece of
substratum was then transferred to a 2 mL bead beating tube containing 1 mL PBS and eighteen 2.38 mm
diameter metal beads (Qiagen). The sample was homogenised in a Fast-Prep 5G benchtop homogeniser
(MP biomedicals) for 40 s at 4 m s1. Using a pipette, and taking care to avoid any solid pieces of biofilm
substratum, the cell supernatant was removed and CFU mL1 counts were determined as described in the
Methods section above.
Results
Characterisation of the biofilms formed in continuous flow conditions
(i) Agar as a solid substratum
We first sought to discern changes in the microbial composition of single-species and polymicrobial biofilms grown
on agar chunks as a substratum (Figure 5 and underlying data (O'Brien et al., 2021)). Viable cell counts were determined
on selective agar plates after rinsing each 5 mm agar chunk (with attached biofilm) and resuspending the attached
cells in 1 mL PBS. When examining the single-species biofilm populations, titres of attached SA and CA were similar
(ca. 106–107 CFU mL1) after 24 h incubation, whereas titres of attached PA were >10-fold greater (at just under
108 CFUmL1). However, over the next 72 h, PA titres increased only slightly (albeit significantly) to >108 CFUmL1,
and SA titres rose to around the same level (i.e. to a titre 2 logs greater than the titre at the 24 h time point). By contrast, CA
titres remained essentially unchanged at the 96 h time point compared with the 24 h time point. These data suggest CA
biofilms establish rapidly with little overall change in cell titres over time. By contrast, PA and SA biofilms also establish
quickly, but continue to grow significantly between sampling points.
Page 13 of 24
F1000Research 2021, 10:801 Last updated: 14 SEP 2021
The situation was different in the polymicrobial cultures. Here, the titres of PA, SA, and CA present on the biofilm
substrata removed sequentially from the same culture vessel remained essentially unchanged at the 24 h and 96 h
sampling points (at around 107 CFU mL1 for PA and SA, and around 105 CFU mL1 for CA). These data suggest that
growth in a polymicrobial culture constrains the population size of individual species in a biofilm.
(ii) EVPL tissue sections as a solid substratum
We next examined biofilm formation on a different biofilm substratum, EVPL tissue (in place of agar chunks) (Figure 6
and underlying data (O'Brien et al., 2021)). No PA, SA or CA cells could be isolated from uninfected EVPL sections
Figure 5. Cell titres derived from biofilms adhered to agar chunks. P. aeruginosa PAO1 (PA), S. aureus 25923 (SA)
and C. albicans SC5314 (CA) cell counts (expressed as CFU mL-1) adhered to 2.5% (w/v) agar chunks after incubation
for 24 h (black bars) or 96 h (white bars) in the continuous-flow culture model. Asterisks indicate significant
(**P < 0.01, ***P < 0.001) differences in CFU mL-1 counts between the 24 h and 96 h time points. Data represent
the mean  standard deviation of three independent biological experiments in which three pieces of biofilm
substratum were sampled per culture vessel per timepoint.
Figure 6. Cell titres derived from biofilms adhered to porcine bronchiole tissue. P. aeruginosa PAO1 (PA),
S. aureus 25923 (SA) and C. albicans SC5314 (CA) cell counts (expressed as CFU mL1) adhered to sections of ex vivo
porcine lung tissue after incubation for 24 h (black bars) or 96 h (white bars) in the continuous-flow culture model.
Asterisks indicate significant (***P < 0.001, ****P < 0.0001) differences in CFUmL1 counts between the 24h and96h
time points. Data represent the mean  standard deviation of three independent biological experiments in which
three pieces of biofilm substratum were sampled per culture vessel per timepoint.
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after any period of incubation. In the single-species biofilm populations, there was no appreciable difference in PA or SA
titres adhered to the substratum at the initial point of sampling (107–108 CFU mL1 at 24 h). Adhered CA titres were
consistently 10-fold lower (ca. 106 CFUmL1) at the same sampling point. After a further 72 h growth, PA and SA titres
increased to >108 CFU mL1, whereas CA titres remained essentially unchanged compared with the titres measured at
24 h. These data indicate that the dynamics of SA biofilm formation varies on different substrata; SA clearly shows more
robust initial colonisation of EVPL substrata compared with agar chunks.
In the triple-species polymicrobial culture, there was no statistically significant difference in adhered PA or SA titres at
the 24 h sampling point (both species achieving 106–107 CFU mL1 at 24 h). We note that this is 10-fold lower than the
PA and SA titres at the same time point in the corresponding biofilms from axenic cultures. Similarly, CA titres in the
polymicrobial biofilms were also 10-fold lower than the CA titres in axenically-cultured biofilms. However, and whereas
adhered CA titres in the polymicrobial biofilms remained unchanged over the following 72 h, PA titres displayed a
marked increase (attaining ca. 108CFUmL1 by the 96 h time point) and SA titres displayed amarked decrease (falling to
ca. 105 CFUmL1) in adhered cell counts. We conclude that the population dynamics of each species can vary by orders
of magnitude, depending on the nature of the biofilm substrata.
Population structure of the planktonic fractions
In parallel with the analysis of species titres in adhered biofilms, we also examined the corresponding titres of each species
in the planktonic (i.e. non-attached) fraction (Figure 7 and underlying data (O'Brien et al., 2021)). Consistent with our
previous findings (O'Brien andWelch, 2019a), steady-state microbial communities were established by 24 h incubation.
There was no appreciable change in CFU mL1 counts of any species cultured as part of an axenic or polymicrobial
population across any point of sampling. Furthermore, there was no discernible difference in CFU mL1 counts of the
planktonic communities grown in the culture vessel flasks containing agar chunks (Figure 7A) or EVPL tissue sections
(Figure 7B). These data indicate that the population dynamics of the biofilms is distinct from the population dynamics of
the surrounding planktonic culture.
Discussion
Here we report a simple method for the robust and reproducible growth of single- and multi-species biofilms on
different substrata. Our model system has been designed to mimic the nutritional environment associated with CF
airways. We previously showed (O'Brien and Welch, 2019a) that the model can maintain very stable steady-state
polymicrobial populations of planktonic cells, even among species that would ordinarily outcompete one another during
ex situ co-cultivation. In the current work, we extend these findings to show that polymicrobial biofilms can be similarly
maintained. Remarkably, we also show that the biofilm composition is far more dynamic than that of the surrounding
planktonic culture, and can vary substantially, even when the planktonic species profile is stable.
A major benefit of our model over existing in vivo approaches is that is inexpensive to set up and requires no specialist
equipment or training to operate. Indeed, the only perceived barrier preventingwider uptake of themodel is in preparation
Figure 7. Cell titres of planktonic cultures. P. aeruginosa PAO1 (PA), S. aureus 25923 (SA) and C. albicans SC5314
(CA) cell counts (expressed as CFU mL1) in the planktonic fraction of single-species and polymicrobial cultures
incubated in ASM in the continuous-flowmodel containing (A) agar chunks or (B) ex vivo porcine lung tissue sections
as the solid substrata. Data represent the mean  standard deviation of two technical replicates collected per
timepoint from three independent biological experiments. P > 0.05 is considered as not significantly different (ns).
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of the ASM culture medium. Mitigating, this generally requires only a few minutes of effort each day (once the stock
solutions have been made up). The primary benefit of the model is that very stable polymicrobial communities can be
rapidly established andmaintained for extended periods of time, and that the planktonic and biofilmmodes of growth can
be studied concurrently in a single experiment. This enables the facile longitudinal study of polymicrobial communities
in vitro, enabling experimental analyses that were previously not possible due to population instability. As such, the
model allows researchers to explore previously inaccessible problems pertaining to microbial ecology, gene expression
and metabolism in polymicrobial communities. For example, we are currently exploiting the system to examine how
mixed-species biofilms such as those found in the CF airways form over time. We are also using the model to examine
how the inclusion of different species or treatment with antimicrobial compounds affect the stability and dynamics of
polymicrobial biofilms longitudinally.
Alongside the ethical benefits and accessibility of an in vitro model for microbial culture, the experimentally tuneable
nature of our model system provides several inherent benefits over existing in vivo CF models (O'Brien and Welch,
2019b). ASM is a chemically-defined synthetic growth medium that has been formulated to closely mimic the nutritional
composition of CF airway secretions (Kirchner et al., 2012; Palmer et al., 2005; Palmer et al., 2007; Turner et al., 2015;
Cornforth et al., 2018). This allows subtle interspecies interactions to be quantified, in real-time, with great reproduc-
ibility. By contrast, the existing animal models display much greater variability, even within a single host species.
Furthermore, culture conditions can be readily modified to enable the detailed study of how a particular variable (such as
iron, for example) impinges upon the formation of polymicrobial biofilms (Mashburn et al., 2005; Palmer et al., 2005).
This level of environmental control is near impossible to achieve with in vivo infection models. We also note that the
experimentally facile nature of our system should permit the study of biofilm formation in other clinically-relevant
polymicrobial infection scenarios such as non-CF bronchiectasis, asthma, or chronic obstructive pulmonary disorders
(COPDs). This can be accomplished through the simple expedient of appropriatelymodifying the nutritional composition
of the culture medium.
The key finding in this report is that mixed-species biofilms comprised of three very different CF-associated pathogens
(a Gram-positive species (SA), a Gram-negative species (PA), and a fungal species (CA)) display distinctly different
compositional dynamics compared with their planktonic counterparts. In particular, we note that the species profiles in
polymicrobial biofilms are consistent with both antagonistic and synergistic interactions. For example, irrespective of the
substrate, adhered CA titres were lower in the polymicrobial biofilms compared with CA titres in biofilms from axenic
CA cultures.
The primary limitation of in vitromodels of infection is a lack of spatial organisation and exclusion of host cells present
when utilising in vivo infection models. We therefore attempted to redress this issue through the introduction of EVPL
tissue sections as biofilm substrata. Porcine airways share a remarkable degree of structural homology with human
airways (Judge et al., 2014; Rogers et al., 2008), and pig lungs are readily available frommost butchers as a by-product of
the food industry. Hence, the inclusion of ex vivo bronchiole tissue sections provide an ethically sustainable approach to
introduce an element of host-microbe interaction and spatial organisation to the model (Harrington et al., 2020; Sweeney
et al., 2021). Indeed, we note that growth on different solid substrata had a profound effect on the compositional dynamics
of polymicrobial biofilms, especially with regards to S. aureus. SA is an effective early coloniser of the CF airways
(Bogaert et al., 2004). When grown on EVPL sections, SA rapidly established a mono-species biofilm with significantly
higher titres comparedwith the biofilm formed on agar chunks. This increasedmicrobial attachment is consistent with the
notion that SA adheres tightly to epithelial cells in the CF microenvironment (Josse et al., 2017), but is less effective at
adhering to abiotic surfaces (agar chunks). However, and whereas SA titres on the agar chunk substrata were stable
between the 24 h and 96 h sampling points, the SA titres on EVPL sections displayed a substantial decline over this
period. By contrast, PA titres in the same biofilms increased, suggesting that the PA progressively displaces SA on the
tissue surface. This reciprocal response (in terms of cell titres) by PA and SA was not observed when agar chunks were
used as a substratum, suggesting that recognition of both airway epithelial cells and SA are required to drive the increased
competitiveness by PA.
Despite the introduction of some level of spatial organisation (in the form of EVPL tissue), the major physiological
limitation of our model compared with in vivo systems is a lack of live host cells and the absence of any accompanying
host-microbe interactions that may modulate microbial behaviour. Nevertheless, and through our comparison of EVPL
tissue and agar chunks as biofilm substrata, we note two things. First, the diminution in SA titres in polymicrobial biofilms
after 96 h growth on EVPL tissue – a diminution not seen on agar chunk substrata – suggests that microbial interaction
with the host tissue may up-regulate the localised production of virulence factors and enhance interspecies competition
(Döring et al., 2011; Malhotra et al., 2019). The implication of this is that the growth of EVPL-associated biofilms in
our continuous-flow model may enable the capture specific temporally-sensitive interactions between the host tissue and
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infecting microbes. Second, agar is a more suitable substratum for examining the long-term, steady-state growth of
polymicrobial biofilms.
The ability to maintain very stable (in terms of composition) long-term polymicrobial biofilms in our setup using
agar chunks as a solid substratum can be exploited for several other applications. First and most obviously, the setup can
be used to investigate the species specificity (for example) of novel antimicrobial or anti-biofilm agents. Using our
system, it is possible to test both a sustained treatment regimen (achieved by adding the test compound(s) at the desired
concentration to the media reservoir) or a short-term treatment regimen, via adding a compound directly to the culture
vessel through the injection ports. The latter may loosely mimic the metabolism and excretion of antimicrobials in situ.
This degree of temporal control is not possible using existing in vivo or in vitro models. Second, new species or strain
variants can be introduced to pre-established polymicrobial biofilms (e.g. addition of PA to a PA-negative community),
allowing facile examination of the impact made by new species or variants. This is directly analogous to the situation seen
in CF, where the acquisition of newmicrobial species or variants can lead to major prognostic changes in the patient. It is
important to note that whenever a new species is introduced, themedium flowrate (Q) may need to be re-optimized. IfQ is
too high, slower-growing organisms may be “washed out” and lost from the culture vessel. Conversely, if Q is too low,
species will grow faster than the rate of media displacement, causing elements of the population to exhaust key nutrients
and enter the stationary phase of growth.
Conclusions
In summary, we present here a simple system for the study of CF-associated polymicrobial biofilms. Importantly, we
have shown that polymicrobial biofilms display distinctly different population dynamics compared with the surrounding
planktonic cells. Moreover, the compositional dynamics of the biofilms depends very much on the substratum employed.
To further extend the utility of our model, we are currently adapting it for use with a wider range of CF-associated
pathogens and testing the possibility of inoculating the system directly with CF patient-derived sputum.
Data availability
Underlying data
Figshare: Underlying data for ‘An in vitro model for the cultivation of polymicrobial biofilms under continuous-flow
conditions’. https://doi.org/10.6084/m9.figshare.14974479.v1 (O'Brien et al., 2021).
This project contains the following underlying data:
• EVPL Biofilms CFUs
• EVPL Supernatant CFUs
• Agar chunks Biofilm CFUs
• Agar chunks Supernatant CFUs
• Selective vs non-selective agar
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
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The manuscript by O'brien et al. describes the development of an in vitro model for the study of 
polymicrobial biofilm, specifically focused on the CF lung environment. This work is timely as the 
importance of polymicrobial colonization, biofilm formation, and infection is increasingly 
recognized as important towards disease outcome. Here, the authors use artificial sputum in a 
continuous flow culture vessel to cultivate biofilms. They examined biofilm formation using two 
different substrates, agar or ex vivo porcine lung tissues. This allows the user to evaluate both 
biofilm growth on the substrate and measure planktonic cell populations in the surrounding 
media. 
 
The manuscript is well written, and the photographs of the apparatus are helpful to the reader 
who wishes to set this up in their own laboratory. The protocol provided is detailed and thorough 
although the production of ASM media seems cumbersome with some steps requiring first hand 
know-how that may introduce variability. For example, the filtration step is stated to take up to 2-3 
days with the membrane being rinsed periodically, it is unclear how this might introduce 
contamination or impact the final media composition. 
 
I have no major comments, minor comments follow:
The protocol states that each species in inoculated at an OD600 of 0.05. This could vary in 
the final cfu/mL depending on the species, especially fungi. It may be more informative to 
state the desired final inoculum in cfu/mL or total CFUs. 
 
○
The substrates are washed three times after incubation and before final quantification of 
biofilm. I wonder if these washes are ever quantified. This may be important to determine if 
the wash step disrupts significant amounts of biofilm for organisms that are loosely 
adherent or reaching maturity and may dislodge due to sheer pressure. This could possibly 
be the case with S. aureus. 
 
○
Figure 4 is not overly informative showing CFUs of overnight cultures. However, if the main ○
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point is that the selective media does not impact growth and quantification, the legend 
should state the selective media used for each species including any antibiotics/antifungals 
in the media. 
 
The authors state in the discussion that the model is amenable to longitudinal studies of 
polymicrobial biofilm for extended periods of time. However, this study only went out to 96 
hrs. It is not clear how long or how stable these communities may be over longer periods. If 
the model allows for study over several days and even weeks this is very powerful. This 
information must be determined for each community, however the authors could address 
their experience with the three-member model community reported in this manuscript in 
the discussion.
○
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O’Brien and colleagues describe a novel model system for the study of polymicrobial biofilms, 
under conditions designed to reflect those of the cystic fibrosis airways. The authors have built on 
their previous study that described a continuous-flow model for cultivation of mixed microbial 
populations. The neat addition, described here, is a metal gauze cage that can be loaded with 
substrata on which microbial biofilm communities can form. In the examples presented, cubes of 
agar or ex vivo porcine bronchioles are used. Culture in artificial sputum media provides 
environmental conditions reflective of the CF airways. 
 
This is a very well presented manuscript, with a carefully considered introduction and sufficient 
methodological detail to enable other users to establish the model in their own labs. The 
discussion describes further applications for the model that all appear realistic. I agree with the 
authors’ assertion that this model has potential to reduce or replace animal use for study of 
polymicrobial biofilms in CF and related conditions, albeit dependent upon the experimental 
question under consideration. 
 
This is primarily a methods paper, so the experimental findings are understandably limited. 
Nonetheless, I thought the observation of steady planktonic microbial density but fluctuating 
biofilm densities/composition was an interesting one. There is clear potential for further 
informative science to be undertaken using this model system. 
 
I have no major criticisms of the work. I thought the study had been well planned, carefully 
executed and nicely presented. I have no doubt that others with interests in polymicrobial 
infections of the CF lung will find the model useful, and I can see it being adapted for study of 
infection in other chronic lung conditions, as the authors suggest. 
 
Below, I include a few minor comments that the authors may wish to consider:
The introduction mentions the limits of in vitro systems as being the lack of host cells and an 
immune system. I would add that most fail to capture the spatial heterogeneity of the 
respiratory tract. Chemical, nutritional, and microbial conditions differ between anatomical 
sites within the upper and lower airways and between different foci of infection within 
lungs. These differences may influence the dynamics of infection, the balance of competing 
pathogens in the airway space and may also contribute to treatment failure. 
 
○
The introduction states that “it should be noted that impaired immune clearance of microbes is 
an inherent feature of CF, which somewhat mitigates the lack of a functional immune system in in 
vitro models.” I take the authors point on this, but it is an oversimplification. Inefficient 
○
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immune clearance is not the same as having no immune response at all. There is still 
potential for interactions between soluble and cellular immune defences and bacterial 
pathogens to influence microbial phenotypes. The authors do partially address this point in 
their discussion, but I think this section of the intro is slightly misleading. 
 
For the presentation of results, I wondered whether CFU/cm2 of substratum might be more 
informative than per ml? If this is too challenging to quantify, then per gram of agar/EVPL 
would at least account for differences in preparation between individual cubes. 
 
○
In the section on the microbial densities within biofilm, I was interested in whether there 
was much difference between biological replicates (i.e. between cubes). Does PA 
outcompete SA every time or does it depend on which gets a foothold first? Do you ever find 
cubes that are completely dominated by a single pathogen? This information is available 
within the source data file, but would be easier to digest in a graph presenting the 
biological replicates for each species side by side. 
 
○
The authors postulated explanations for the relative success of PA vs SA on EVPL are 
intriguing, but this section should acknowledge that only one strain of each species has 
been tested. PAO1 is fast growing compared to many PA isolates from CF and this may 
contribute to the observed outcomes. 
 
○
Although clearly beyond the scope of this manuscript, I was interested as to how the 
authors think the model may need to be adapted to better reflect the environmental 
conditions of the CF lung now that patients are moving over to CFTR modulator therapies?
○
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